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Abstract
Objectives To describe a randomized controlled trial (RCT) of digital breast tomosynthesis including synthesized two-
dimensional mammograms (DBT) versus digital mammography (DM) in a population-based screening program for breast cancer
and to compare selected secondary screening outcomes for the two techniques.
Methods This RCT, performed in Bergen as part of BreastScreen Norway, was approved by the Regional Committees for
Medical Health Research Ethics. All screening attendees in Bergen were invited to participate, of which 89% (14,274/15,976)
concented during the first year, and were randomized to DBT (n = 7155) or DM (n = 7119). Secondary screening outcomes were
stratified by mammographic density and compared using two-sample t-tests, chi-square tests, ANOVA, negative binomial
regression and tests of proportions (z tests).
Results Mean reading time was 1 min 11 s for DBTand 41 s for DM (p < 0.01). Mean time spent at consensus was 3 min 12 s for
DBTand 2 min 12 s for DM (p < 0.01), while the rate of cases discussed at consensus was 6.4% and 7.4%, respectively for DBT
and DM (p = 0.03). The recall rate was 3.0% for DBTand 3.6% for DM (p = 0.03). For women with non-dense breasts, recall rate
was 2.2% for DBT versus 3.4% for DM (p = 0.04). The rate did not differ for women with dense breasts (3.6% for both). Mean
glandular dose per examination was 2.96 mGy for DBT and 2.95 mGy for DM (p = 0.433).
Conclusions Interim analysis of a screening RCT showed that DBT took longer to read than DM, but had significantly lower
recall rate than DM. We found no differences in radiation dose between the two techniques.
Key Points
• In this RCT, DBT was associated with longer interpretation time than DM
• Recall rates were lower for DBT than for DM
• Mean glandular radiation dose did not differ between DBT and DM
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Digital breast tomosynthesis (DBT) in combination with dig-
ital mammography (DM) has been claimed to be superior to
DM alone in prospective studies of cancer detection in
European breast cancer screening programs [1–4]. However,
recall rates have been shown to vary between studies.
Globally, a limited number of studies using DBT for
screening have reported complete data on interval breast can-
cers [5–7], and there is presently limited knowledge about the
characteristics of the cancers detected with DBT versus DM
[5, 7–9]. Further, most studies have evaluated results of DBT
in addition to DM, which substantially increases the radiation
dose [10–12]. Replacing the DM in DBT +DMwith synthetic
mammograms (SM), a 2D mammographic image reconstruct-
ed from the projection data obtained during the DBT acquisi-
tion, has been suggested as a solution and has recently shown
promising results with respect to early performance measures
in European screening programs [3, 8, 9, 13]. In addition, the
sensitivity of DBTamong women with dense breasts has been
questioned [14–16].
Logistical aspects including increased examination and
reading times, the burden on IT systems related to storage,
power and speed, and the financial costs are additional aspects
that need to be explored to fully evaluate the cost-
effectiveness and feasibility of using DBT + SM in organized
screening programs.
To address some of the aforementioned gaps in knowledge,
we conducted a randomized controlled trial (RCT) using DBT
+ SM versus DM only: the Tomosynthesis trial in Bergen (the
To-Be trial). The To-Be RCT started in January 2016 and
spanned one screening round (2 years). Our study objectives
for this paper were to describe the design of this RCT and to
report results of interim analyses after the first year of the trial.
We compared selected secondary screening outcomes, such as
examination time, time spent on screen reading and consen-
sus, rates of cases discussed at consensus, recall rates due to
abnormal mammographic findings, and mean glandular dose
for DBT + SM (hereafter referred to as DBT) and DM, by
mammographic density.
Material and methods
The To-Be trial is approved by the Regional Committees for
Medical and Health Research Ethics and registered at
ClinicalTrials.gov (NCT02835625).
Study design of RCT
The To-Be trial is an RCT aimed at investigating early perfor-
mance measures and economical aspects when using DBT
versus DM in a screening program for breast cancer (Fig. 1).
The trial was performed in Bergen, as a part of BreastScreen
Norway, a population-based breast cancer screening program
targeting women aged 50–69 years. The program is
administred by the Cancer Registry of Norway and has been
run since 1995. The program is described in detail elsewhere
[17].
All women who attended screening at the screening unit in
Bergen, 2016 and 2017, received a request about participation
in the trial. Those who agreed and signed an individual con-
sent form were randomized to screening with either DBT or
DM, using a 1:1 allocation ratio. The target group for the
screening site in Bergen counted about 45,000 women for
the actual screening round. Assuming an attendance rate of
75% and 90% participation in the trial, the RCTwas powered
to identify a statistically significant increase of 25–30% in the
rate of screen-detected breast cancers. Information related to
the screening examination (screening outcome, procedures
performed during recall, mammographic features including
density, histologic tumor characteristics, treatment etc.) were
reported continuously to the Cancer Registry of Norway by
the Breast Center at HaukelandUniversity Hospital in Bergen.
Participants will be followed for 2 years after screening, to
identify interval breast cancers and cancers in the next screen-
ing round.
To avoid bias in the performance of the trial, no results of
the surveillance or the analyses, except screening attendance
rate and participation rate in the trial, were communicated to
the professionals who worked in the practical part of the trial.
Study setting
The To-Be trial was performed in an everyday screening set-
ting. All women underwent standard two-view (craniocaudal
and mediolateral oblique views) DBT or DM performed by
two radiographers. We used imaging equipment from GE
(SenoClaire 3D Breast Tomosynthesis™). The DBT acquisi-
tion consisted of nine low-dose exposures over an angle of
25°, reconstructed into 1-mm and 10-mm planes, as well as
SM. Screen reading was performed on IDI workstations, each
with two 5-megapixel moni tors (GE Heal thcare
MammoWorkstation Version 4.7.0 Image Diagnost). The stor-
age requirement for the raw data and processed image data
was 500–3000 MB per examination for DBT and 60–80 MB
for DM.
Screening examinations were read using independent dou-
ble reading. Prior DM screening mammograms were available
for subsequently screened women. The standard reading pro-
tocol included two views of each breast for DM and two-view
synthethic mammograms and 1-mm planes of each breast for
DBT. Slabs were vailable for DBT and used in challenging
cases, mainly during the consensus meetings. Each breast was
assigned a score of 1–5 by each radiologist. A score of 1
indicated screening examination negative for abnormality;
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2, probably benign; 3, intermediate suspicion; 4, probably
malignant; and 5, high suspicion of malignancy. If either ra-
diologist assigned a score of 2 or higher to one or both breasts,
a consensus meeting (hereafter referred to as consensus) with
two or more radiologists was held to determine whether to call
the woman back for further assessment (recall).
Up to four prior examinations were available at the work-
station both for initial screen reading and consensus.
Assessment of recalled women included additional mammo-
graphic imaging and/or ultrasound, potentially a needle biop-
sy and sometimes anMRI. Recall assessment took place at the
Breast Center at Haukeland University Hospital.
Eight radiologists with 0–19 years of experience in screen
film and/or digital mammography (mean 7 years) took part in
screen reading, consensus and follow-up assessments
(Appendix, Table 5). All radiologists who did screen reading
also performed the assessments for recalled women and diag-
nostic examinations. DBTwas available as a diagnostic meth-
od at the Breast Center for about 1 year prior to starting the
trial, but had not been used for screening. All radiologists
attended a training session with DBT before they started
screen reading in the trial. Moreover, a pilot study performed
8 weeks pre-trial included about 300 DBT screening cases.
Study population of interim analyses
These first results from the To-Be trial reports pre-planned
interim analyses of selected secondary outcome measures
from the first year of To-Be, 2016. A total of 21,786 women
were invited to screening in Bergen, whereas 15,976 (73%)
attended and 14,274 (89%) agreed to participate in the trial.
Altogether, 7155 women were randomized to DBT and 7119
to DM (Fig. 2).
Definition of secondary outcome measures
Examination time was measured as the time spent from when
the woman entered the examination room until she left: time
was manually registered using a stopwatch for 438 and 535
randomly selected women screened with DBT and DM, re-
spectively, during March 2017.
Fig. 1 Study design of the To-Be trial in Bergen, a randomized controlled trial using digital breast tomosynthesis in combination with synthesized 2D
images (DBT) versus digital mammography (DM), in Breast Screen Norway. Excluded because of a lack of data on mammographic density
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Time spent on initial screen reading and consensus was
measured from the time the radiologist entered the women’s
ID on the computer until the result of the reading/consensus
was registered, using software developed for the trial. Initial
screen reading time was measured for each radiologist, while
consensus time was measured per woman without taking the
number of participating radiologists into account.
The consensus rate was defined as the number of screening
examinations discussed at consensus, divided by the total
number of screening examinations. For each radiologist, the
rate was estimated as the number of examinations given a
score of 2 or higher (2+) divided by the number of screen
readings per radiologist. The recall rate was the number of
women recalled (post-consensus) because of abnormal mam-
mographic findings divided by the number of women
screened. For each radiologist, the recall rate was estimated
as the number of cases they had read which were discussed at
consensus and recalled divided by the number of screen read-
ings by that radiologist.
Measures of volumetric breast density (VBD) and mean
radiation dose per exposure (mean glandular dose, MGD)
were calculated from the raw image data and data extracted
from the DICOM header, using automated software (Volpara
version 1.5.1, Volpara Health Technologies Ltd, Wellington,
NZ) [18]. Average MGD per screening examination was cal-
culated as the sum of the radiation doses reported by the soft-
ware for both views and breasts divided by two. VBD was
classified into a Volpara density grade (VDG) based on the
following scale outlined by Volpara [19]: VDG 1 (VBD <
4.49%); VDG 2 (4.5–7.49%); VDG 3 (VBD 7.5–15.49%)
and VDG 4 (VBD ≥ 15.5%). These categories are analogous
to the BI-RADS 5th edition density categories a–d [20–22].
Statistical analysis
We estimated mean and median time for screening examina-
tion, screen reading and consensus in minutes and seconds
(minutes:seconds). For screen reading we excluded outlier
values above 10 min and for consensus values above 15
min, assuming that radiologists had been interrupted. The out-
liers occurred similarly for DBT and DM. Further, we calcu-
lated mean values of MGD per examination. Rates of consen-
sus and recall were presented per 100 screening examinations
with 95% confidence intervals (95% CI). Analyses were strat-
ified by screening technique (DBTandDM), screening history
(prevalent or subsequent attendance), time since trial com-
mencement (1–4, 5–8 and 9–12 months), the radiologists’
expertise in screen reading of DM before the start of the trial,
and by cumulative number of DM and DBT screen reads in
the trial, and mammographic density (VDG 1–4).
Trends in consensus and recall rates according to reading
volume were tested for by a negative binomial regression
model. We also used negative binomial regression to estimate
the risk ratio (RR) and 95% confidence interval (95% CI) of
consensus and recall for DBT using DM as the reference.
Crude and adjusted RRs were calculated. Covariates in the
adjusted models included mammographic density and an in-
teraction effect between screening technique and density.
We used STATA version 15 (Stata Corp, TX) for all statis-
tical analyses and tested differences across categories for
Fig. 2 Study design and study
population for interim analyses
after 1 year of running the To-Be
trial in Bergen, 2016
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statistical significance using two-sample t-tests, chi-square
tests, ANOVA and tests of proportions (z test). A p value of
less than 0.05 was considered statistically significant.
Results
Among women included in the interim analyses, 1% (185/
14,274) were excluded because of missing mammographic
density data. Information from 14,089 women was thus in-
cluded in analyses: 7037 screened with DBT and 7052
screened with DM. Women were, on average, 59 years old
at screening in both groups (p = 0.469) (Table 1). The distri-
bution of characteristics detailed in Table 1 did not differ be-
tween the two groups.
Women spent an average time (minutes:seconds) of 5:24
(median 5:13) for DBT and 4:19 (median 4:07) for DM in the
screening examination room (p < 0.01) (Table 2). Average and
median times spent on initial screen reading and consensus
were generally higher for DBT compared to DM.
The rates of cases discussed at consensus were 6.4% for
DBT and 7.4% for DM (p = 0.03) (Table 3). These rates did
not differ among prevalent examinations (13.0% for both
DBT and DM, p = 0.97), which was in contrast to the subse-
quent examinations, where the rate was 5.2% for DBT and
6.3% for DM (p < 0.01). We observed an increasing rate of
cases discussed at consensus by VDG for DBT (p for trend <
0.01), but not for DM (p for trend = 0.078).
The eight radiologists’ reading volume before and during
the trial period varied (Appendix, Table 5). A score of 2+,
resulting in a consensus meeting, was given for an average
of 4.5% of the DBTand 5.4% of the DM screen reads for each
of the radiologists (Appendix, Table 6). The consensus rate
decreased with 0.1% for DBT (p = 0.4) and 0.2% for DM (p =
0.05) per 1000 DM screen reads prior to start-up of the trial.
The recall rate was 3.0% for DBT and 3.6% for DM (p =
0.03) (Table 3). This rate did not differ for the two techniques
among prevalently screened women (6.3% for DBTand 6.2%
for DM, p = 0.95), in contrast to subsequently screened wom-
en where the rate was 2.3% for DBT and 3.1% for DM (p <
0.01). For DBT, recall rates increased from 2.2% for women
with VDG 1 to 3.6% for women with VDG 4 (p for trend <
0.01). No statistically significant difference was observed for
women screened with DM (p = 0.93). The number of DM
screen reads before the trial period did not significantly alter
the recall rates for DBT or DM (p = 0.6 for DBT and p = 0.8
for DM) (Appendix Table 5).
The cumulative reading volume of DBT during the trial
showed a non-significant trend of a decreasing consensus rate
(RR = 0.95, p = 0.3) (Appendix Table 6 and Fig. 4). For DM,
this trend reached statistical significance (RR = 0.93, p =
0.04). For recall rates, a non-significant trend of decreasing
value with cumulative reading volume during the trial period
was observed both for DBTand DM (p = 0.8 for DBTand p =
0.4 for DM).
The adjusted risks of consensus and recall were lower for
DBT than for DM: RR 0.71 (95% CI 0.52–0.97) for consen-
sus and 0.58 (95% CI 0.38–0.89) for recalls (Table 4). The
interaction between screening technique and mammographic
density was not stastistically significant when modelling the
risk of consensus. However, the risk of recall among women
screened with DBT increased for VDG 3 versus VDG 1 (p =
0.033), and displayed a trend toward increased values for
VDG 4 versus VDG 1 (p = 0.061), compared with DM.
MGD per examination was 2.96 mGy for DBT and 2.95
mGy for DM (p = 0.433) (Fig. 3). It did not differ with mam-
mographic density, nor within the density groups or between
screening techniques.
Discussion
In the first year of this RCTusing DBTand DM in population-
based breast cancer screening, we found lower consensus and
recall rates among women screened with DBT than with DM.
Our density-stratified analyses identified that recall rates were
lower for DBTonly for women with non-dense breasts (VDG
1 and VDG 2). Time spent both on screen reading and con-
sensus was longer for DBT than for DM. Average MGD did
not differ between the two techniques.
The lower recall rate for DBT compared to DM found in
our interim analyses supports results from other studies,
Table 1 Characteristics of the study population screened with digital
breast tomosynthesis including synthesized 2D mammography (DBT) or
digital mammography (DM) in the To-Be trial in Bergen, 2016
DBT DM p value
(n = 7037) (n = 7052)
Age (years)
Mean/median 59/59 59/59 0.469*




Screening history (% of screened women) 0.883**
Prevalently screened 15.7% 15.6%
Subsequently screened 84.4% 84.4%
Mammographic density 0.248**
VDG 1 21.0% 20.4%
VDG 2 44.8% 43.7%
VDG 3 26.1% 27.1%




although recall rates have been shown to vary [1–4, 8, 9].
Different reading protocols and screening logistics might be
some of the reasons for this variance [23–26]. Reducing recall
rates below 3% in organized screening programs seems more
challenging than reducing a recall rate of 10% or higher.
Regardless of screening technique, there is limited evidence
onwhat the ideal recall rate is, according to false positive screen-
ing results, cancer detection and breast cancermortality [27, 28].
More than 65% of the women in our study were classified
as having non-dense breast (VDG 1 or VDG 2). Women with
non-dense breasts had a lower recall rate when screened with
DBT than when screened with DM. However, recall rates did
not differ between DBT and DM for women with dense
breasts (VDG 3 or VDG4). Moreover, the effect of mammo-
graphic density on the risk of recall tended to be larger for
DBT than for DM, a relevant finding in a breast cancer screen-
ing program given that it applies to the larger proportion of
screening attendees in our population. Given the established
knowledge about the increasing risk of breast cancer with
mammographic density, the increase in recall rate with density
seems reasonable.
The consenus rates were also higher for women with dense
rather than fatty breasts, both for DBT and DM. This is pos-
sibly related to the complex parenchyma and the need for a
Table 2 Mean and median time
spent in the examination room per
woman, at initial screen reading
per radiologist, and at consensus
for digital breast tomosynthesis
with synthesized 2D (DBT) ver-
sus digital mammography (DM),
in the To-Be trial in Bergen, 2016
DBT DM p value*
Examination time per woman N = 438 N = 534
Mean/median (min:s) 5:24/5:13 4:19/4:07 < 0.01
Initial screen reading time per reader (min:s) N = 7029 N = 7048
All screens 1:11/0:54 0:41/0:26 < 0.01
Prevalent screens 1:10/0:53 0:33/0:19 < 0.01
Subsequent screens 1:11/0:54 0:43/0.27 < 0.01
p for trend* 0.850 < 0.01
Reading time stratified by time since start of trial
1–4 months 1:18/1:00 0:42/0:29 < 0.01
5–8 months 0:56/0.46 0:33/0:21 < 0.01
9–12 months 1:11/0.54 0:45/0:27 < 0.01
p for trend** < 0.001 < 0.001
Reading time stratified by mammographic density
VDG 1 1:01/0:47 0:39/0:24 < 0.01
VDG 2 1:09/0:55 0:40/0:26 < 0.01
VDG 3 1:15/0:58 0:44/0:28 < 0.01
VDG 4 1:17/0:58 0:42/0:28 < 0.01
p for trend** < 0.001 < 0.001
Time spent on consensus (min:s) N = 451 N = 519
All 3:12/2:42 2:12/1:55 < 0.01
Prevalent screens 2:51/2:27 1:51/1:36 < 0.01
Subsequent screens 3:22/2:49 2:20/2:04 < 0.01
p for trend* < 0.001 < 0.001
Consensus time stratified by time since start of trial
1–4 months 3:31/3:14 2:08/1:48 < 0.01
5–8 months 2:45/2:14 1:54/1:42 < 0.01
9–12 months 3:06/2:39 2:21/2:05 < 0.01
p for trend** 0.012 0.014
Consensus time stratified by mammographic density
VDG 1 3:15/2:33 2:15/2:03 < 0.01
VDG 2 3:14/2:47 2:12/1:51 < 0.01
VDG 3 3:16/2:48 2:14/1:56 < 0.01
VDG 4 2:52/2:30 2:00/1:51 < 0.01




second opinion. The consensus meeting used in BreastScreen
Norway can be considered an educational activity where
Bpositive^ cases are discussed and prior screening exams are
carefully considered before a final decision about recall is
made. In a broader perspective, our results, demonstrating a
lower percentage of cases needing to be discussed at consen-
sus, suggest that DBT may reduce the percentage of cases
needing third arbitrating reads in other programs. As far as
we know, no other studies have reported consensus rates for
DBT previously. It is possible that the dense cases discussed at
consensus were more obvious to recall than the fatty cases.
The radiologists might thus need less time to agree about
recall for the dense versus the fatty cases.
The burden of increased examination and screen reading
time from DBT is a critical issue for screening programs. The
increased examination time was mainly due to time spent on
explaining to the women how the x-ray machine would move
and to make the x-ray tube ready for exposure. This extra time
is expected to be reduced or resolved in subsequent screening
rounds.We demonstrated that the average reading timewas 30
s longer for DBT than for DM at initial screen reading (1:11
versus 0:41, respectively). The Oslo Tomosynthesis Screening
Trial (OTST) reported that an additional 41 s was needed for
reading DBT compared to DM [2], while results from the
STORM trial, Malmo trial and a study by Dang et al showed
an increase of 44 s [1], 30 s [4] and 54 s [29], respectively. Our
results therefore represent the minimum increase in time spent
on initial screen reading reported in the literature to date.
However, the reading time varied between radiologists. We
found that some radiologists were fast readers while other
used more time. We consider this variability amongst the ra-
diologists as individual-related rather than trial-related since
the findings were independent of screening technique and vol-
ume of screen reads during their career.
In our study, time spent on screen reading and consensus
was lowest 5–8months after the start of the trial. This could be
because this period was during the summer months, when
fewer women were screened, resulting in low power in the
estimate. The low reading and consensus time could
also be related to a learning effect. A workshop reviewing
Table 3 Numbers (n) and percentages (%) of screening examinations discussed at consensus and recalls for digital breast tomosynthesis with
synthesized 2D (DBT) versus digital mammography (DM), in the To-Be trial in Bergen, 2016













































p for trend* < 0.01 < 0.01 < 0.01 < 0.01






































































cancer cases dismissed by one of the two readers was per-
formed 7–8 months after the start of the trial, as a part of the
usual quality assurance in the program. This might have con-
tributed to readers deliberating longer at screen reading and
may account for the increased reading time in the third period,
8–12 months after trial commencement.
Results from other studies indicate the need for training and
workshops before reading DBT in screening [30, 31]. In our
study, the radiologists’ experience in DM screen reading before
the trial period varied from beginners to very experienced, the
latter with more than 100,000 screen reads during their career
as a breast radiologist. Not all radiologists participated in screen
reading DBT in the pilot, which was performed 8 weeks before
the trial commenced. We identified a significant decreasing
trend of consensus with reading volume during the trial for
DM, but not for DBT. The volume of screen reads prior to
the trial did not show any correlation with either consensus or
recall rate, neither for DBT nor DM. Our study presents results
only for the first year of the trial, whichmight be considered the
learning period. Further analyses including a longer study pe-
riod might shed a different light on the issue. In this trial radi-
ologists without experience in screen reading did training on
test sets, shadow reading within the trial and performed clinical
mammography with DBT. In retrospect, the pilot could have
been extended to 6 months to enhance reader preparation, and
additional workshops could have been held to make sure all
participating radiologists had read a minimum number of neg-
ative and false positive examinations, screen-detected and
Table 4 Risk ratio (RR) of
undergoing consensus and being
recalled adjusted for
mammographic density for digital
breast tomosynthesis with
synthesized 2D (DBT) versus
digital mammography (DM) in
the To-Be trial in Bergen, 2016
RR of consensus RR of recall
RR 95% CI p value RR 95% CI p value
Screening technique
DM 1.00 – – 1.00 – –
DBT 0.71 (0.52–0.97) 0.032 0.58 (0.38–0.89) 0.013
Mammographic density
VDG 1 1.00 – – 1.00 – –
VDG 2 1.20 (0.95–1.53) 0.129 1.00 (0.73–1.37) 0.979
VDG 3 1.34 (1.04–1.72) 0.025 1.14 (0.81–1.59) 0.472
VDG 4 1.44 (1.04–2.00) 0.027 1.08 (0.68–1.72) 0.752
Screening technique and mammographic density (interaction)
DBT–VDG 1 1.00 – – 1.00 – –
DBT–VDG 2 1.17 (0.81–1.68) 0.410 1.31 (0.79–2.18) 0.302
DBT–VDG 3 1.41 (0.96–2.07) 0.077 1.77 (1.05–3.01) 0.033
DBT–VDG 4 1.43 (0.88–2.33) 0.143 1.93 (0.97–3.84) 0.061
Fig. 3 Mean glandular dose
(MGD) per examination among
women screened during the first
year of the To-Be trial, overall and
by Volpara density grade (VDG),
stratified by imaging technique
(digital breast tomosynthesis
including synthesized 2D
mammograms [DBT] or digital
mammography [DM])
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interval breast cancers before the trial started. Although a roster
was established at the start of the trial to ensure all radiologists
read equal numbers of DBT and DM cases, this plan was not
strictly followed because of varying individual work speeds
and an unforeseen high volume of mammography outside of
the screening program. Moreover, participating radiologists
were not all exposed to the same number of DBT cases. The
issues encountered in the implementation of the To-Be trial
represent real-world screening challenges and provide novel
insights that should inform other breast screening programs
when planning DBT evaluations.
We found no statistically significant difference in radiation
dose per examination between DBT and DM. Gennaro et al
[10] reported doses per view (CC, MLO), also calculated by
Volpara, for examinations acquired using a different unit/
system and found the doses to be statistically significantly
higher for DBT than for DM for both views. In a per view
comparison (DBT and DM exposures of the same breasts dur-
ing the same compression session) they found an average in-
crease in DBT dose compared to DM of 38% (range 0–75%).
Similarly, the Oslo Tomosynthesis Screening Trial used DBT
systems from the same vendor as Gennaro et al and found, on
average, dose per view to be 23% higher with DBT than DM
when machine-reported doses were compared [12].
Using a system from yet another manufacturer, Lång et al
[4] did not report dose values; instead, the automatic exposure
control was set to yield an average dose of 1.2 mGy for DM
and 1.6 mGy for DBT for a standard breast model. This gives
an expected per view ratio of MGDDBT/MGDDM of 1.33. For
our system the manufacturer stated that the target MGD for
DBT using automatic exposure control was equivalent to the
MGD per view for DM, i.e. an expected ratio of approximate-
ly 1. The absence of a difference betweenMGDwith DBTand
DM observed in our study is therefore in line with how the
system is set to operate by the manufacturer.
During the study period, routine quality assurance of the col-
lected data and control activities were performed. We consider
this to be one important strength of this study. We used an RCT
design, the most reliable research design to compare screening
modalities, and embedded this in a population-based screening
program; these features of our trial minimize bias and increase
the generalizability to other organized screening programs.
A limitation of this study is the short time spent on training
and workshops in DBT for radiographers before the start of the
trial, which could have influenced the results in either direction
[30, 31]. Moreover, we have not presented breast cancer detec-
tion data; this decision was based on per protocol power esti-
mation, which showed that 2 years of screening—one screen-
ing round—was needed to show a 25–30% difference in the
rate of screen-detected breast cancer between DBT and DM.
The moderate number of cases included in the analyses also
represents a limitation in this study, particularly when stratify-
ing into subgroups. Despite these limitations, we present our
interim results to inform other population-based screening pro-
grams of selected secondary screening outcomes from an RCT
of DBT and DM, in particular the estimated recall rate, screen
reading time and radiation metrics, all of which matter to
screening practice and research planning. To the best of our
knowledge, there are no published secondary screening out-
comes from other RCTs of DBT screening.
In conclusion, after the first year of running an RCT com-
paring DBT and DM, including about 7000 screened women
in each arm, we showed a lower recall rate for women
screened with DBT than DM. Our RCT sheds further light
on the burdens of interpretation time and radiation dose,
which are key factors in population-based screening. Time
spent on screen reading and on consensus was longer for
DBT than for DM. MGD measured by automated software
on a GE SenoClair machine did not differ between the two
techniques. Our results are somewhat different from other
published studies and call for RCTs from different screening
populations and with equipment from different vendors in
order to gain evidence about the consequences of
implementing DBT with synthesized mammograms, as a
screening technique in population-based screening programs.
Acknowledgements We would like to thank all the radiographers, radi-
ologists and others at the Breast Center, Department of Radiology at
Haukeland University Hospital, Bergen, Norway, for their extensive
work, help and support in the performance of this study. Solveig
Hofvind is the principal investigator for the study and head of
BreastScreen Norway. She is employed at the Cancer Registry of
Norway, which administers the screening program. Nehmat Houssami
is funded by a Breast Cancer Research Leadership Fellowship from the
National Breast Cancer Foundation (Australia).
Funding This study has received funding by the Research Council of
Norway (Project # 247941).
Compliance with ethical standards
Guarantor The scientific guarantor of this publication is Solveig
Hofvind.
Conflict of interest The authors of this manuscript declare no relation-
ships with any companies whose products or services may be related to
the subject matter of the article.
Statistics and biometry No complex statistical methods were necessary
for this paper.
Informed consent Written informed consent was obtained from all sub-
jects (patients) in this study.
Ethical approval Institutional review board approval was obtained.
Methodology
• prospective
• randomized controlled trial
• performed at one institution
Eur Radiol
Appendix
Table 5 Characteristics of the radiologists involved in the To-Be trial in Bergen, screen-reads (n), rates of consensus (score 2+) and recalls for DBTand
DM by radiologist




DBT in the trial
(month, year)
DM screen-readings
before the trial period
(n)
Screen reads (n) Score 2+ Consensus
(%)
Recall (%)
DBT DM DBT DM DBT DM
R1 36 Feb 2016 Feb 2016 0 2978 3884 4.1 % 5.3 % 2.4 % 3.1 %
R2 32 May 2014 Apr 2016 10744 920 383 7.1 % 8.1 % 3.8 % 3.7 %
R3 47 Oct 2010 Jan 2016 15085 1781 1344 4.3 % 4.9 % 3.1 % 3.8 %
R4 36 May 2012 Jan 2016 23801 1208 1563 4.4 % 6.7 % 3.1 % 4.7 %
R5 50 Jan 2009 Aug 2016 24015 453 502 4.6 % 9.2 % 3.1 % 4.4 %
R6 43 Sept 2007 Jan 2016 37361 1634 1177 4.8 % 5.2 % 3.1 % 3.8 %
R7 40 Sept 2008 Jan 2016 92590 2155 3789 4.2 % 4.0 % 2.7 % 3.0 %
R8 50 Sept 1997 Jan 2016 109152 2945 1462 4.4 % 6.6 % 3.2 % 4.9 %
p for trend 0.4 0.05 0.6 0.8
Total 14 074 14 104 4.5 % 5.4 % 3.0 % 3.6 %
p for trend tested by a negative binomial regression model
Table 6 Cumulative number of
DBTand DM screen-reads during
the first year of the To-Be trial in
Bergen and subsequent rates of
consensus and recalls
Number of DBT screen-reads
in To-Be before current reading
Screening examinations (n) Consensus (%) Recall (%)
0-499 3955 4.8 % 3.2 %
500-999 3420 4.8 % 2.8 %
1000-1499 2707 4.5 % 2.9 %
1500-1999 1914 3.4 % 2.7 %
2000-2499 1155 4.7 % 3.1 %
2500+ 923 4.4 % 3.0 %
p for trend 0.3 0.8
Total DBT 14074 4.5 % 3.0 %
Number of DM screen-reads
in To-Be before current reading
0-499 3922 6,0 % 4,1 %
500-999 3002 5,6 % 3,6 %
1000-1499 2446 5,9 % 4,2 %
1500-1999 1063 3,4 % 1,5 %
2000-2499 1000 4,3 % 2,2 %
2500+ 2671 5,0 % 3,8 %
p for trend 0.04 0.4
Total DM 14104 5,4 % 3,6 %
p for trend tested by a negative binomial regression model
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